Clinical Trial

Low-Dose Radiotherapy With Retlirafusp Alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Name: Low-Dose Radiotherapy With Retlirafusp Alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma — clinical trial record (NCT07682376)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study aims to evaluate the efficacy and safety of neoadjuvant low-dose radiotherapy combined with Retlirafusp alfa and chemotherapy in the treatment of resectable locally advanced esophageal squamous cell carcinoma.

Trial Details

NCT Number	NCT07682376
Lead Sponsor	Harbin Medical University Collaborators: Henan Cancer Hospital, Shanxi Province Cancer Hospital, Peking Union Medical College Hospital
Conditions	Esophageal Squamous Cell Carcinoma (ESCC)
Enrollment	96 participants
Start Date	2026-06-10
Primary Completion	2028-05-30 (estimated)
Study Completion	2029-05-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-02